Small molecule designed to target metal binding site in the alpha2I domain inhibits integrin function

Area of Science:

• Biochemistry
• Molecular Biology
• Drug Discovery

Background:

• Integrin alpha2beta1 is a key molecule in cellular adhesion and a potential target for therapeutic interventions.
• Understanding the structural basis of integrin-ligand interactions is crucial for designing effective drugs.

Purpose of the Study:

• To establish design criteria for molecules targeting the closed conformation of the alpha2I domain.
• To identify novel inhibitors of alpha2beta1 integrin based on these criteria.

Main Methods:

• Development of specific molecular design criteria for targeting the alpha2I domain's closed conformation.
• Screening of tetracyclic Streptomyces products, specifically aromatic polyketides, for inhibitory activity.

Main Results:

• Identified specific design criteria for molecules binding to the closed alpha2I domain via Mg(2+) in the MIDAS.
• Discovered that certain tetracyclic aromatic polyketides meet these criteria and inhibit alpha2beta1 integrin.
• Characterized these inhibitors as distinct from previously described allosteric inhibitors of alphaI domain integrins.

Conclusions:

• Aromatic polyketides represent a promising class of novel alpha2beta1 integrin inhibitors.
• The identified inhibitors bind directly to the MIDAS region in a non-allosteric manner.
• These findings provide a foundation for developing new drugs targeting integrin alpha2beta1.